The objectives of this randomized controlled trial, of individuals with heart failure (HF) secondary to ischemic heart disease, are:

1) To examine the impact of colchicine on the composite outcome of CV death, HF hospitalization, urgent HF visit, cardiac arrest, or ischemic cardiovascular events (define as myocardial infarction, ischemic stroke, or arterial revascularization).

2) To examine the impact of thiamine on the composite outcome of CV death, HF hospitalization or urgent HF visit.

As a 2×2 factorial RCT, the first factorial will randomize participants to colchicine 0.5 mg daily or to placebo.

The second factorial will be a prospective, randomized, open-label, blinded-endpoint (PROBE) design with participants randomized to open-label thiamine 200-300 mg daily or to no thiamine (control).

COLT-HF is one of the studies that is part of the CHF Alliance, a pan-Canadian, patient-driven network of heart failure reseachers.

Study Type

Interventional - Drug

Study Design

2x2 factorial RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2022 - 2027



Canadian Institutes for Health Research (CIHR)

Back To Top